BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 25261661)

  • 21. [Correlation analysis among expression of ERCC-1, metallothionein, p53 and platinum resistance and prognosis in advanced non-small cell lung cancer].
    Huang PY; Liang XM; Lin SX; Luo RZ; Hou JH; Zhang L
    Ai Zheng; 2004 Jul; 23(7):845-50. PubMed ID: 15248926
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Individual-level data on the relationships of progression-free survival, post-progression survival, and tumor response with overall survival in patients with advanced non-squamous non-small cell lung cancer.
    Imai H; Takahashi T; Mori K; Ono A; Akamatsu H; Shukuya T; Taira T; Kenmotsu H; Naito T; Murakami H; Endo M; Nakajima T; Yamamoto N
    Neoplasma; 2014; 61(2):233-40. PubMed ID: 24299320
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Comparison of treatment efficacy of the second and the third generations of chemoradiotherapy regimens containing platinum on advanced non-small cell lung cancer].
    Wang YM; Guo LJ; Li LS; Li P; Zheng J; Li L
    Ai Zheng; 2005 Dec; 24(12):1514-7. PubMed ID: 16351804
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of NF-E2-related factor 2 in predicting chemoresistance and prognosis in advanced non-small-cell lung cancer.
    Yang H; Wang W; Zhang Y; Zhao J; Lin E; Gao J; He J
    Clin Lung Cancer; 2011 May; 12(3):166-71. PubMed ID: 21663859
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical and prognostic significance of OPN and VEGF expression in patients with non-small-cell lung cancer.
    Lin Q; Guo L; Lin G; Chen Z; Chen T; Lin J; Zhang B; Gu X
    Cancer Epidemiol; 2015 Aug; 39(4):539-44. PubMed ID: 26123318
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Osteopontin is a novel prognostic biomarker in early-stage non-small cell lung cancer after surgical resection.
    Yan CH; Lv M; Li H; Song X; Yan F; Cao S; Ren X
    J Cancer Res Clin Oncol; 2015 Aug; 141(8):1371-8. PubMed ID: 25555465
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel association between CD74 polymorphisms and hematologic toxicity in patients with NSCLC after platinum-based chemotherapy.
    Tan X; Wu Q; Cai Y; Zhao X; Wang S; Gao Z; Yang Y; Li X; Qian J; Wang J; Su B; Chen H; Han B; Jiang G; Lu D
    Clin Lung Cancer; 2014 Jan; 15(1):67-78.e12. PubMed ID: 24220096
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Class III β-tubulin in advanced NSCLC of adenocarcinoma subtype predicts superior outcome in a randomized trial.
    Vilmar AC; Santoni-Rugiu E; Sørensen JB
    Clin Cancer Res; 2011 Aug; 17(15):5205-14. PubMed ID: 21690572
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Survival rates and tolerability of platinum-based chemotherapy regimens for elderly patients with non-small-cell lung cancer (NSCLC).
    Costa GJ; Fernandes AL; Pereira JR; Curtis JR; Santoro IL
    Lung Cancer; 2006 Aug; 53(2):171-6. PubMed ID: 16757059
    [TBL] [Abstract][Full Text] [Related]  

  • 30. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.
    Pirker R; Pereira JR; von Pawel J; Krzakowski M; Ramlau R; Park K; de Marinis F; Eberhardt WE; Paz-Ares L; Störkel S; Schumacher KM; von Heydebreck A; Celik I; O'Byrne KJ
    Lancet Oncol; 2012 Jan; 13(1):33-42. PubMed ID: 22056021
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum ferritin is elevated in advanced non-small cell lung cancer patients and is associated with efficacy of platinum-based chemotherapy.
    Shi HB; Li XD; Jiang JT; Zhao WQ; Ji M; Wu CP
    J Cancer Res Ther; 2014; 10(3):681-5. PubMed ID: 25313760
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Elevated circulating level of osteopontin is associated with advanced disease state of non-small cell lung cancer.
    Chang YS; Kim HJ; Chang J; Ahn CM; Kim SK; Kim SK
    Lung Cancer; 2007 Sep; 57(3):373-80. PubMed ID: 17513004
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vitamin D deficiency is associated with a poor prognosis in advanced non-small cell lung cancer patients treated with platinum-based first-line chemotherapy.
    Ma K; Xu W; Wang C; Li B; Su K; Li W
    Cancer Biomark; 2017; 18(3):297-303. PubMed ID: 27983538
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic information of serial plasma osteopontin measurement in radiotherapy of non-small-cell lung cancer.
    Ostheimer C; Bache M; Güttler A; Reese T; Vordermark D
    BMC Cancer; 2014 Nov; 14():858. PubMed ID: 25416631
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum osteopontin levels are highly prognostic for survival in advanced non-small cell lung cancer: results from JMTO LC 0004.
    Isa S; Kawaguchi T; Teramukai S; Minato K; Ohsaki Y; Shibata K; Yonei T; Hayashibara K; Fukushima M; Kawahara M; Furuse K; Mack PC
    J Thorac Oncol; 2009 Sep; 4(9):1104-10. PubMed ID: 19620934
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Osteopontin and thrombospondin-1 play opposite roles in promoting tumor aggressiveness of primary resected non-small cell lung cancer.
    Rouanne M; Adam J; Goubar A; Robin A; Ohana C; Louvet E; Cormier J; Mercier O; Dorfmüller P; Fattal S; de Montpreville VT; Lebret T; Dartevelle P; Fadel E; Besse B; Olaussen KA; Auclair C; Soria JC
    BMC Cancer; 2016 Jul; 16():483. PubMed ID: 27422280
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overexpression of MAC30 is Resistant to Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer.
    Chen R; Fen Y; Lin X; Ma T; Cai H; Ding H
    Technol Cancer Res Treat; 2016 Dec; 15(6):815-820. PubMed ID: 26376695
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of POLK polymorphisms with platinum-based chemotherapy response and severe toxicity in non-small cell lung cancer patients.
    Shao M; Jin B; Niu Y; Ye J; Lu D; Han B
    Cell Biochem Biophys; 2014 Nov; 70(2):1227-37. PubMed ID: 24948471
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003.
    Mack PC; Redman MW; Chansky K; Williamson SK; Farneth NC; Lara PN; Franklin WA; Le QT; Crowley JJ; Gandara DR;
    J Clin Oncol; 2008 Oct; 26(29):4771-6. PubMed ID: 18779603
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor-associated macrophages (TAMs)-derived osteopontin (OPN) upregulates PD-L1 expression and predicts poor prognosis in non-small cell lung cancer (NSCLC).
    Li Y; Liu H; Zhao Y; Yue D; Chen C; Li C; Zhang Z; Wang C
    Thorac Cancer; 2021 Oct; 12(20):2698-2709. PubMed ID: 34423566
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.